SLC
NTLA icon

Second Line Capital’s Intellia Therapeutics NTLA Stock Holding History

Second Line Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-63,027
Closed -$1.09M – 173
2025
Q3 		$1.09M Hold
63,027
– – 0.23% 55
2025
Q2 		$591K Sell
63,027
-16,672
-21% -$137K 0.14% 64
2025
Q1 		$567K Sell
79,699
-51,423
-39% -$519K 0.15% 65
2024
Q4 		$1.53M Buy
+131,122
New +$2.05M 0.41% 42

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Second Line Capital's NTLA Position: Q4 2025 in Review

Second Line Capital sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 63,027 shares — an estimated $1.09M sold.

Second Line Capital first reported a position in NTLA in Q4 2024 and held it in 4 quarters. The position peaked at $1.53M in Q4 2024. 291 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Second Line Capital reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Second Line Capital sold 63,027 Intellia Therapeutics shares in Q4 2025, an estimated $1.09M.
  • Second Line Capital first reported a position in Intellia Therapeutics in Q4 2024 and held it in 4 quarters.
  • Second Line Capital's Intellia Therapeutics position peaked at $1.53M in Q4 2024.
  • 291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Second Line Capital's 13F filing for Q4 2025, filed 17 Feb 2026.